Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q2 FY26 Earnings Presentation
22 slides from Alembic Pharmaceuticals's earnings presentation, Nov 4, 2025
Slide 1: Filing cover letter to stock exchanges
Date: 4th November, 2025 To, To, The Manager, The Manager, Department of Corporate Services, Listing Department, BSE Limited National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, ‘Exchange Plaza’, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 53357
Slide 2: Alembic Pharmaceuticals Limited Investor Presentation Q2 FY26
Alembic Pharmaceuticals Limited Investor Presentation Q2 FY26
Slide 3: Safe Harbour Statement
Safe Harbour Statement The materials and information presented herein may include forward looking statements , which reflect current expectations, projections, and assumptions. These statements are inherently subject to risks and uncertainties that could cause actual results or outcomes to differ ma
Slide 4: Quarterly Snapshot
Quarterly Snapshot Key Highlights Revenue INR 19.10 Bn India Branded Business +16% YoY Achieved a 5% YoY growth with quarterly revenues of INR 6.39 billion. US Generics EBIDTA INR 3.24 Bn Reported a 21% YoY increase driven by key product launches and market share +26% YoY EBIDTA Margin ~17% gains in
Slide 5: Revenue Summary
Revenue Summary INR Bn Business Q2 FY26 Q2 FY25 Y-o-Y Q1 FY26 Q-o-Q H1 FY26 H1 FY25 Y-o-Y Formulations India Branded Business 6.39 6.09 5% 5.99 6% 12.38 11.81 5% US Generics 5.66 4.67 21% 5.23 8% 10.89 9.28 17% Ex-US Generics 3.92 2.98 31% 3.28 16% 7.19 5.68 27% API 3.14 2.74 15% 2.61 17% 5.75 5.32
Slide 6: India Branded Business – Performance
India Branded Business – Performance Revenue Q2 FY26 Revenue in Past 5 Years CAGR: 12% INR Bn 23.39 6.39 22.00 6.09 20.63 19.26 19% 22% 14.96 Animal Health 28% 28% Acute 53% 51% Specialty Q2FY25 Q2FY26 FY21 FY22 FY23 FY24 FY25 Sales Mix Q2 FY26 > The India Branded Business recorded 5% growth with re
Slide 7: India Branded Business – Rx Driven Rankings
India Branded Business – Rx Driven Rankings Top Brands with Rank and Market Share Driving Overall Prescription Business BRANDS Rank MS% Q2 BRANDS Rank MS% 133.2 Q2 FY 26* Q2 Q2 128.7 FY 26* FY 26* FY 26* 0.24 0.23 AZITHRAL 1 30.2 WIKORYL 3 10.4 ALTHROCIN 1 86.3 BROZEET-LS 3 6.7 CRINA-NCR 1 29.9 ISOF
Slide 8: Animal Health Business
Animal Health Business Revenue Q2 FY26 Growth: 17% INR Mn Revenue in Past 5 Years CAGR: 24% INR Mn 1380 Billions 4305 3553 2860 2320 1180 1841 Q2FY25 Q2FY26 FY21 FY22 FY23 FY24 FY25 Sales Mix Q2 FY26 > Alembic operates in the Livestock, Poultry, and Companion Animal Antibiotic segments. > Market lea
Slide 9: US Generics Business
US Generics Business Revenue Q2 FY26 Growth: 21% INR Bn Revenue in Past 5 Years INR Bn 21.63 19.57 17.30 5.66 16.66 15.72 4.67 Q2FY25 Q2FY26 FY21 FY22 FY23 FY24 FY25 Approved ANDAs > Well-established US front-end with a strong customer base. Total 226* * Includes 21 Tentative Approvals > 7 products
Slide 10: Ex-US Generics Business
Ex-US Generics Business Revenue Q2 FY26 Growth: 31% INR Bn Revenue in past 5 Years CAGR: 12% INR Bn 3.92 12.43 2.98 10.52 8.52 7.75 Q2FY25 Q2FY26 7.79 > Achieved 31% YoY growth in Q2, momentum sustained globally through targeted execution and strong customer demand. > Key partnerships active in Euro
Slide 11: API Business
API Business Revenue Q2 FY26 Revenue in past 5 Years Growth: 15% INR Bn CAGR: 4% INR Bn 12.46 3.14 11.66 11.33 2.74 9.55 9.39 Q2FY25 Q2FY26 > Growth of 15% on annual basis is led by surge in volumes, partially offset by price erosion across the markets. > 1 US DMF filed in Q2 FY26. 141 Cumulative DM
Slide 12: R&D Dosage Form-wise ANDA Approval and Launch – H1 FY26
R&D Dosage Form-wise ANDA Approval and Launch – H1 FY26 Continued investment in building product pipelines INR Bn Approval 8 7 15.8% Launched 14.0% 6 12.8% 4 7.8% 4 7.6% R&D Spend 2 2 8.4 2 1 1 1 1 7.2 R&D % of sales 6.7 4.8 5.2 0 OSD OSD-Onco Injectables Injectables-Onco Opthalmology Derma Approved
Slide 13: Q2 Financials Summary – Profit & Loss statement
Q2 Financials Summary – Profit & Loss statement INR Bn Particulars Q-2 FY25 Q-1 FY26 Q-2 FY26 YoY(%) QoQ(%) H-1 FY 25 H-1 FY 26 YoY(%) Revenue from Operations 16.48 17.11 19.10 16% 12% 32.10 36.21 13% Other Income 0.17 0.07 0.07 0.19 0.13 -29% Total Income 16.65 17.17 19.17 15% 12% 32.29 36.34 13% M
Slide 14: Q2 Financials Summary – Balance sheet
Q2 Financials Summary – Balance sheet INR Bn As at 31st March, As at 30th Particulars 2025 September, 2025 Non-current assets Property, plant and equipment 25.24 26.12 Capital work-in-progress 8.37 9.03 Other Intangible assets 0.00 2.22 Financial Assets 1.27 1.29 Deferred tax assets 1.66 1.65 Other
Slide 15: Yearly Financials
Yearly Financials INR Bn Revenue EBIDTA Net Profit 6.65 10.53 10.53 6.16 66.72 9.61 # 5.84 62.29 56.53 4.97 # 53.06 7.79 # FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 EBIDTA margin % Capex ROCE % 20% 5.75 25% * 16% 4.67 14% # 15% # 4.12 3.45 15% *# 16%*# 14%*# FY22 FY23 FY24 FY25 FY2
Slide 16: Sustainability – Alembic's ESG Targets
Sustainability >A l e m b i c ’ s E S G Ta r g e t s Net Zero by 2050 • 63% GHG Emission reduction by 2034 Water Neutrality by 2027 50,000 trees by 2027 • 90% GHG Emission reduction by 2050 (Approved by SBTi) Environment Social Governance • We are one of the 10 Indian Pharma companies with approved
Slide 17: Company Overview
Company Overview Alembic Pharmaceuticals Ltd. Investor Presentation Q2 FY26
Slide 18: Company at a Glance
Company at a Glance Mission Team Size ANDA Filings R&D Centers Manufacturing Facilities Improve Healthcare with 16,500+ 269 (Sep 30,2025) 2 10 innovation, commitment and Trust Prescribers in India Field Force Brands Net Zero Target Products in the USA 2,44,000 5,500+ 207 2050 170 Alembic Pharmaceuti
Slide 19: Value Proposition
Value Proposition Developing a specialty drug Supplying APIs to 60+ countries pipeline for India globally Established presence in Chile & Exploring opportunities in UAE Injectables Ranks 20th in the Indian Expanding product portfolio in the formulations market USA Consistent, high dividend payout St
Slide 20: The Journey
The Journey 2012 Formed a JV, Rhizen , for 2025 2006 Indore facility NCE Research FDA- Commissioned 2007 & approved API facility Acquired Acquired Utility Dabur’s Indian Therapeutics Cardiology, GI & 2013 Limited 1907 Gynecology 2010 Launched first 2013 2023 brands NDA with a Established by Pharmace
Slide 21: Robust Infrastructure
Robust Infrastructure Product brand logo Dosage Form Last USFDA Audit International Generics F1 - Panelav General Oral Solids July’24 F2 - Panelav Oncology Oral Solids Mar’24 Oncology Injectables Oct’24 F3 - Karkhadi General Injectables Mar’23 Ophthalmic F2 - Panelav F3 - Karkhadi F4 - Jarod General
Slide 22: Thank You
Thank You For further queries, please contact: Investor Relations Advisors Mr. Ajay Desai Adfactors PR Pvt. Ltd. ajay.desai@alembic.co.in 022-6695 3681 Snighter Albuquerque snighter.a@adfactorspr.com Darshan Mankad darshan.mankad@adfactorspr.com 2nd Floor, Prime Corporate Park Sahar Road, Andheri Ea
Alembic Pharmaceuticals — Q2 FY26 Earnings Presentation on 6ix